Merz, Kvvit strike China-region deal for INBRIJA

Version 1

Merz Therapeutics and Jiangxi Kvvit Pharmaceutical have signed an exclusive license and collaboration agreement to advance INBRIJA, an inhaled levodopa product for intermittent “OFF” episodes in adults with Parkinson’s disease, across mainland China, Hong Kong, and Macao. Under the deal, Kvvit will handle local development, regulatory work, and commercialization, while Merz will receive upfront, milestone, supply, and tiered royalty payments. The companies said Kvvit will not receive manufacturing rights. INBRIJA is already authorized in the U.S. and Europe for on-demand treatment of OFF episodes in people taking levodopa-based therapy. (businesswire.com)

Why it matters: While this is a human neurology deal rather than a veterinary one, it’s still relevant to animal health professionals tracking cross-border biopharma strategy, inhaled drug delivery, and China market access. The partnership follows a familiar playbook: an established therapy with prior approvals in Western markets is paired with a regional partner to manage local registration and launch. INBRIJA’s profile also stands out because it uses pulmonary delivery to bypass gastrointestinal absorption challenges and provide rapid symptom relief, a formulation approach that continues to draw interest across therapeutic areas. (businesswire.com)

What to watch: Watch for regulatory filing timelines in China and any disclosures on development milestones, launch sequencing, or local clinical requirements. (businesswire.com)